Going beyond EGFR: Evaluating technologies for molecular genetic testing in NSCLC

July 28, 2020
11 am to 12 pm EDT

Sponsored by


Webinar Description:
All metastatic NSCLC patients should have molecular testing to identify the presence of driver mutations and actionable targets, like T790M, L858R and exon 19 deletions in EGFR.

The Institut National du Cancer in France developed a special program in 2006 and supported a national network of 28 hospital platforms to organize molecular testing. Since 2015, NGS implementation had a major impact on laboratory organization and broad genomic sequencing has disseminated ahead of a demonstrated association with better survival, and without economic evaluation. We decided to evaluate the MassARRAY technology, an open platform, for lung cancer, breast and colon tumors or melanoma, in comparison with NGS.

Here, Dr. Pencreach will present the results of their retrospective technical analysis after one year of routine NSCLC molecular testing with the MassARRAY System from a biological/clinical and economical point of view.

Learning Objectives:

  • Best practices for molecular testing in non-small cell lung cancer
  • How to evaluate the best technology for your laboratory
  • Sensitivity required for optimal molecular testing


Erwan Pencreach imageErwan Pencreach, PharmD, PhD
Department of Molecular Oncology
Strasbourg University Hospital, France

University lecturer / associate professor - Hospital practitioner
Strasbourg Faculty of Medicine and University Hospital, Strasbourg (France)

  • Medical Biologist at the Dpt. of Molecular Oncology
  • Teaching : In charge of the teaching of Biochemistry and Molecular Oncology
  • Research topics (Inserm U1113) : hypoxia, RE stress, immune response and tumor progression

Alexander Sartori imageDr. Alexander Sartori
Staff Scientist, Scientific Affairs

Alexander Sartori is chemist with PhD from the University of Kiel in cell biology; Alexander has 20 years’ experience in the Life Science industry and broad technical and application skills with a focus on oncology. For the past 10 years he was managing various collaborations and international consortia. In 2015 Alexander joined Agena Bioscience and in his current position he is leading Agena’s Scientific Affairs’ oncology activities globally with a focus on liquid biopsies.

Cost: No cost!

Schedule conflict? Register and you'll receive a copy of the recording!